Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer’s disease, in murine biological matrices. This method addresses the challenges...
Saved in:
| Main Authors: | Emma H. Doud, Kasi Hansen, Kathryn A. Haynes, Kierra Eldridge, Jaison Arrivalagan, Nitin Charbe, Lais Da Silva, Sara K. Quinney, Amber L. Mosley, Stacey J. Sukoff Rizzo, Paul R. Territo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2537118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
by: Pranay Sinha, et al.
Published: (2022-01-01) -
Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system
by: Lingti Kong, et al.
Published: (2025-05-01) -
A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases
by: Haoxiang Hu, et al.
Published: (2025-04-01) -
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
by: Jaeyeong Jeong, et al.
Published: (2025-05-01) -
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study
by: Kristen D. Onos, et al.
Published: (2022-01-01)